ArticleJournal of the American Heart Association2024
Gut Dysbiosis in Patients With Fontan Circulation.
Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Beyond Short-Chain Fatty Acids: Defining the Gut-Liver Metabolic Signature in Fontan Circulation.Journal of gastroenterology and hepatology · 2026Article
- Reply to "Letter on: Reduced Perfusion Pressure as a Predictor of Protein-Losing Enteropathy After Fontan Procedure: Beyond Central Venous Pressure".Pediatric cardiology · 2026Article
- Proteomic Remodeling in Fontan Circulation Associated with Fibrosis and Time-Dependent Immune-Metabolic Alteration.International journal of molecular sciences · 2026Article
- Beyond Passive Congestion: The Inflammatory Gut-Liver Axis in Fontan Circulation.Pediatric cardiology · 2026Review
- Bile Acid Pool Expansion and Hemodynamic Associations of the Secondary-to-Primary Bile Acid Ratio in Adult Fontan Circulation.Pediatric cardiology · 2026Article
- Low-grade endotoxemia as an additional prothrombotic mechanism in adults with Fontan circulation.Journal of thrombosis and thrombolysis · 2026Article
- The Gut Microbiome in Congenital Heart Disease: Dysbiosis, Intestinal Barrier Injury, and Translational Opportunities Across the Childhood-A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Association Between Hemodynamic Parameters and Gut Microbiota in Fontan Circulation: A Cross-Sectional Study.Journal of the American Heart Association · 2026Article
- Association between the gut microbiome and neurodevelopmental outcomes in infants with congenital heart disease: A prospective cohort study.JPEN. Journal of parenteral and enteral nutrition · 2026Article
- Circulating Biomarkers in Failing Fontan Circulation: Current Evidence and Future Directions.Journal of cardiovascular development and disease · 2025Review
- Overcoming borders: International cooperation in re-use and re-interpretation of omics data in Fontan circulation.International journal of cardiology. Congenital heart disease · 2025Article
- The Role of the Gut Microbiota in Heart Failure: Pathophysiological Insights and Future Perspectives.Medicina (Kaunas, Lithuania) · 2025Review
- Fontan-Associated Liver Disease.Seminars in liver disease · 2025Review
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
- Protein-losing enteropathy after the Fontan procedure - A cardiologist's and gastroenterologist's perspective.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe process underlying Fontan pathophysiology is multifactorial and may include gut dysbiosis (GD). We investigated the presence of GD and elucidated its correlation with Fontan pathophysiology. METHODS AND
resultsGut microbiomes of 155 consecutive patients with Fontan pathophysiology and 44 healthy individuals were analyzed using 16S rRNA sequencing of bacterial DNA extracted from fecal samples. GD was evaluated on the basis of α and ß diversities of the gut microbiome and was compared with natural log-transformed C-reactive protein, hemodynamics, von Willebrand factor antigen (a bacterial translocation marker), Mac-2 binding protein glycosylation isomer (a liver fibrosis indicator), peak oxygen uptake, and heart failure hospitalization. Patients with Fontan exhibited GD in terms of α and ß diversities as compared with controls (
conclusionsPatients with Fontan pathophysiology exhibited GD compared with healthy individuals, and GD was linked to failed hemodynamics and systemic inflammation with a poor prognosis. Therefore, GD may play a pivotal role in a failing Fontan status, including Fontan-associated liver disease, through GD-associated systemic inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.